Skip to content

Dezocine combined with dexmedetomidine in monitoring anesthesia care of ablation on hysteromyoma with HIFU

Dezocine combined with dexmedetomidine in monitoring anesthesia care of ablation on hysteromyoma with HIFU

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096909
Enrollment
Unknown
Registered
2025-02-08
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pain

Interventions

Combined Group :dezocine combined with dexmedetomidine
Traditional Group :Remifentanil combined with dexmedetomidine

Sponsors

Zhongshan City People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1 Subjects and their authorized clients voluntarily sign informed consent for this study; 2 18-65 years old; 3 ASA grade I-III; 4 Selected HIFU therapy on hysteromyoma.

Exclusion criteria

Exclusion criteria: 1 History of upper respiratory tract infection within 2 weeks before surgery; 2 Severe liver and kidney dysfunction; 3 History of drug abuse; 4 History of allergy to drugs and their ingredients involved in this study; 5 Unable to cooperate due to impairment of hearing, speech, cognitive or central nervous system disease or mental system disease; 6 Patients or family members refuse to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Pain Numeric Rating Scale score;Ramsay Sedation Scale score;The mean number of intraoperative tachycardia;The mean number of intraoperative low blood oxygen saturation;

Countries

China

Contacts

Public ContactChen Gu

Zhongshan City People's Hospital

420206559@qq.com+86 136 3222 2464

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026